휴온스, 휴온스랩 합병 반대의사 접수…주식매수청구건 관건

Huons' merger with subsidiary Huons Lab risks transferring proprietary pharmaceutical technology (HyDIFFUZE platform) away from its largest shareholder, sparking disputes over fair valuation and corporate succession concerns. The case highlights critical tensions between corporate restructuring and shareholder protection, as the valuation of private company assets becomes contentious. This mirrors broader biotech industry trends where minority shareholders challenge merger ratio fairness and question whether restructuring genuinely benefits investors or facilitates management succession.